Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.42 USD | -2.10% | +7.17% | +225.73% |
May. 31 | Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 | CI |
May. 20 | Transcript : Jasper Therapeutics, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+225.73% | 392M | |
+42.59% | 739B | |
+32.34% | 598B | |
-5.88% | 353B | |
+17.22% | 318B | |
+3.31% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+5.98% | 164B |
- Stock Market
- Equities
- JSPR Stock
- News Jasper Therapeutics, Inc.
- Jasper Therapeutics Says First Patient Dosed in Phase 1b/2a Trial of Briquilimab for CSU Treatment